RxDoctor Payments Data

Imedla Angelica Cirilo, MD

Internal Medicine · Manchester, CTNPI 1962780940

Payments from drug & device makers

$1,226in general payments, 2019–2025

Across 69 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$321
  • Pfizer$210
  • AbbVie$132
  • Scilex Pharmaceuticals Inc.$114
  • GSK$111
  • Lilly USA, LLC$96
  • plus $242 from 7 others

What the payments were for

  • Food & beverage$1,226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,226 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$97,136
Medicare patients
206
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$82,631
JardianceEmpagliflozin31$54,183
EliquisApixaban46$52,041
TrulicityDulaglutide27$49,126
JanuviaSitagliptin Phosphate26$41,610
MounjaroTirzepatide34$35,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,414
Advair HfaFluticasone Propion/Salmeterol15$5,915
SynthroidLevothyroxine Sodium58$5,342
Duloxetine Hcl104$4,864
Rosuvastatin Calcium270$3,510
Atorvastatin Calcium372$3,459
Epinephrine14$3,026
Albuterol Sulfate HfaAlbuterol Sulfate130$2,695
Lidocaine27$2,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$96$84,57961 claims
Novo NordiskOzempic$321$82,63172 claims
PfizerEliquis$210$52,04146 claims
MerckJanuvia$76$41,61026 claims
GSKTrelegy Ellipta$111$19,41430 claims
AbbVieSynthroid$132$5,34258 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Manchester

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →